T cell lymphomas are notoriously difficult to treat because immunotherapy, despite being one of the most effective therapies for treating cancer, can't easily distinguish cancerous T cells from ...

A new, highly sensitive cell therapy was able to wipe out three different kinds of solid tumors in mice, an important advance in an area where CAR-T cells have long struggled. But significant ...

As a world leader in the immuno-oncology field, Dr. Zihai Li has long been at the forefront of cancer immunotherapy.

Fred Hutch Cancer Center scientists have developed an experimental strategy to give genetically engineered CAR T cells help they'd normally find within lymph nodes — but on the go, within the tumor.

A cancer drug class best known for attacking tumors may also help your immune system remember them better. Researchers at ...

A modified herpes virus boosted immune T cell infiltration in glioblastoma tumors and was associated with improved survival.

The first engineered cell therapy has come to the fight against solid tumors. Fox Chase Cancer Center has begun using Tecelra, an FDA-approved treatment for synovial sarcoma.

UCLA scientists have developed a next-generation CAR-T cell therapy that can overcome the immunosuppressive tumor microenvironment, a protective shield that tumors use to weaken immune cells, block ...

New research shows lymph nodes aren’t just cancer bystanders, they’re the command centers fueling immune attacks. Surgically removing them along with tumors may weaken treatment, while preserving them ...

Bristol Myers Squibb will pay T-cell engager company Janux Therapeutics $50 million in the near term as part of a collaboration to work on a novel tumor-activated therapeutic. The resulting candidate ...

T cell lymphomas are notoriously difficult to treat because immunotherapy, despite being one of the most effective therapies for treating cancer, can’t easily distinguish cancerous T cells from ...